Genelux Corp Stock Price, News & Analysis

Genelux (NASDAQ: GNLX) reported third quarter 2025 results and clinical updates on Nov 5, 2025. The company held $21.0 million in cash, cash equivalents, short-term investments and restricted cash as of Sept 30, 2025, which management expects will fund operations into the third quarter of 2026. Topline data from the OnPrime Phase 3 ovarian cancer registrational trial is now anticipated in the second half of 2026. Additional interim data from two systemically delivered Olvi-Vec lung cancer trials are expected in Q4 2025 and through 2026. Q3 2025 net loss was $8.0 million (loss per share $0.21); R&D was $4.7 million and G&A was $3.5 million.

Key program notes: OnPrime remains enrolling in the U.S.; the Independent Data Monitoring Committee has recommended continuation; company believes positive PFS without OS decrement could support traditional FDA approval based on a Type D meeting.

Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, has announced its participation in the H.C. Wainwright Global Investment Conference. CEO and Chairman Thomas Zindrick and CFO Matt Pulisic will engage in a fireside chat on September 9, 2025, at 2:30 p.m. ET, moderated by Biotech Equity Research Analyst Emily Bodnar.

The company will also conduct one-on-one meetings with institutional investors during the conference. A replay of the session will be available for approximately 90 days on Genelux's IR page.

Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, reported Q2 2025 financial results and provided pipeline updates. The company's lead candidate Olvi-Vec is advancing in multiple clinical trials, with key data readouts expected. The Phase 3 OnPrime/GOG-3076 registrational trial in platinum-resistant/refractory ovarian cancer (PRROC) is progressing toward topline data in H1 2026.

Financial highlights include cash position of $28.1 million as of June 30, 2025, providing runway into Q3 2026. Q2 2025 resulted in a net loss of $7.5 million ($0.20 per share), compared to $6.6 million ($0.22 per share) in Q2 2024. The company strengthened its leadership team with Eric Groen joining as General Counsel and Head of Business Development.

Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, has appointed Eric Groen as General Counsel, Corporate Secretary, Chief Compliance Officer and Head of Business Development, effective July 1, 2025.

Groen brings over 20 years of experience in the life sciences industry, notably serving at Rani Therapeutics and Amgen, where he played a key role in the $10 billion Onyx Pharmaceuticals acquisition. As part of his appointment, Groen received an inducement award of 270,000 stock options at $2.83 per share, vesting over four years.

Genelux Corporation (NASDAQ: GNLX) reported Q1 2025 financial results and business updates. The company's lead candidate Olvi-Vec showed promising developments across multiple cancer indications. Key highlights include: FDA feedback indicating potential traditional approval for platinum-resistant/refractory ovarian cancer treatment pending Phase 3 trial results expected in 1H 2026; preliminary data from Phase 1b/2 trial showing 71% disease control rate in small cell lung cancer patients; and ongoing Phase 2 trial progress in non-small cell lung cancer. Financially, Q1 2025 showed a net loss of $7.5 million ($0.21 per share), with cash position of $35.1 million. The company completed a $10.5 million offering in March 2025, extending runway into Q3 2026. Matthew Pulisic joined as new CFO, bringing 19 years of biopharmaceutical industry experience.

Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, has announced its participation in the upcoming Citizens Life Sciences Conference in New York on May 7-8, 2025. CEO and Chairman Thomas Zindrick and CFO Matt Pulisic will engage in a fireside chat with Biotech Equity Research Managing Director Silvan Tuerkcan on May 8 at 1:30 p.m. ET. The discussion will focus on the company's clinical-stage programs and upcoming milestones.

The event will be accessible via webcast, with a replay available for 90 days on Genelux's IR page. The company will also conduct one-on-one meetings with institutional investors during the conference.

Genelux (NASDAQ: GNLX) reported its Q4 and full year 2024 financial results, highlighting key developments in its oncology pipeline. The company reached alignment with FDA on the approval pathway for Olvi-Vec in Platinum Resistant/Refractory Ovarian Cancer, with topline data expected in H1 2026.

In clinical developments, preliminary Phase 1b/2 data for Olvi-Vec in Advanced Small-Cell Lung Cancer showed a 71% disease control rate, with two partial responders and favorable safety profile. The company strengthened its financial position with a $10.5 million underwritten offering at $3.50 per share.

Financial highlights include:

• Cash position of $30.9 million as of December 31, 2024
• R&D expenses increased to $19.0 million from $12.8 million in 2023
• G&A expenses rose to $12.7 million from $11.6 million in 2023
• Net loss of $29.9 million ($0.95 per share) compared to $28.3 million ($1.16 per share) in 2023

Genelux (Nasdaq: GNLX) has announced the pricing of an underwritten offering of 3,000,000 shares of common stock at $3.50 per share, expected to raise gross proceeds of $10.5 million. The late clinical-stage immuno-oncology company plans to use the net proceeds for working capital and general corporate purposes, including the continued clinical development of Olvi-Vec.

The offering is expected to close on March 26, 2025, subject to customary closing conditions. Titan Partners Group, a division of American Capital Partners, is serving as the sole bookrunner for the offering. The securities are being offered through an effective shelf registration statement previously filed with the SEC.

Genelux and Newsoara BioPharma have announced promising preliminary data from their Phase 1b/2 trial of Olvi-Vec immunochemotherapy in platinum-relapsed/refractory small cell lung cancer patients. The trial showed a 71% disease control rate (5/7 patients), with two achieving partial responses.

Key highlights include:

• One participant achieved ~79% tumor reduction
• Three participants reached stable disease with tumor reductions of 24-29.2%
• All patients with disease control experienced reductions in all target lesions
• Treatment demonstrated favorable safety profile with mostly mild to moderate side effects

The data suggests Olvi-Vec's potential as a platinum resensitizing agent beyond ovarian cancer. The trial continues enrollment for dose escalation to determine the recommended intravenous dose for Phase 2.